AR067897A1 - Compuestos para el tratamiento de hepatitis c - Google Patents
Compuestos para el tratamiento de hepatitis cInfo
- Publication number
- AR067897A1 AR067897A1 ARP080103488A ARP080103488A AR067897A1 AR 067897 A1 AR067897 A1 AR 067897A1 AR P080103488 A ARP080103488 A AR P080103488A AR P080103488 A ARP080103488 A AR P080103488A AR 067897 A1 AR067897 A1 AR 067897A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- dialkylamino
- alkylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) en la que: R1es CO2R5 o CONR6R7; R2 es furanilo, pirrolilo, tienilo, pirazolilo, isoxazolilo, isotiazolilo, imidazolilo, oxazolilo, tiazolilo, oxadiazolilo, triazolilo o tetrazolilo, y está sustituido con 0-2 sustituyentes seleccionados de oxo, amino, alquiltio, alquilo y haloalquilo, y 1 sustituyente seleccionado de CO2R5, CON(R12)2 y COR13; R3 es hidrogeno, halo, alquilo, alquenilo, hidroxi, benciloxi o alcoxi; R4 es cicloalquilo; R5 es hidrogeno o alquilo; R6 es hidrogeno, alquilo, alquilSO2, cicloalquilSO2, haloalquilSO2, (R9)(R10)NSO2 o (R11)SO2; R7 es hidrogeno o alquilo; R8 es hidrogeno, alquilo, cicloalquilo, (cicloalquil)alquilo, alquilcarbonilo, cicloalquilcarbonilo, haloalquilcarbonilo, alcoxicarbonilo, alquilSO2, cicloalquilSO2, haloalquilSO2, aminocarbonilo, (alquilamino)carbonilo, (dialquilamino)carbonilo, bencilo, benciloxicarbonilo o piridinilo; R9 es hidrogeno o alquilo; R10 es hidrogeno o alquilo; R11 es azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, tiomorfolinilo, homopiperidinilo, homopiperazinilo o homomorfolinilo, y está sustituido con 0-1 sustituyentes alquilo; R12 es hidrogeno, alquilo, alcoxialquilo, aminoalquilo, (alquilamino)alquilo, (dialquilamino)alquilo o (R11)alquilo; R13 es azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, tiomorfolinilo, homopiperidinilo, homopiperazinilo o homomorfolinilo, y está sustituido con 0-3 sustituyentes seleccionados de alquilo, alcoxialquilo, amino, alquilamino, dialquilamino, R11, aminoalquilo, (alquilamino)alquilo, (dialquilamino)alquilo, (R11)alquilo o CO2R5 o R13 es como en formulas (2); o R13 es una diamina bicíclica [4.3.0] o [3.3.0] unida al carbonilo a través de un nitrogeno, y está sustituido con 0-2 sustituyentes R8 o R13 es como en formulas (3), R14 es hidrogeno, alquilo, cicloalquilo, (cicloalquil)alquilo, aminoalquilo, (alquilamino)alquilo, (dialquilamino)alquilo o bencilo; R15 es hidrogeno, alquilo, cicloalquilo, (cicloalquil)aIquilo, aminoalquilo, (alquilamino)alquilo, (dialquilamino)alquilo o bencilo; o NR14R15 tomados conjuntamente es azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, N-(alquil)piperazinilo, morfolinilo, tiomorfolinilo, homopiperidinilo o homomorfolinilo; R16 es hidrogeno o alquilo; R17 es hidrogeno, alquilo o cicloalquilo; y X es metileno, un enlace o no está presente; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95481407P | 2007-08-09 | 2007-08-09 | |
| US4994408P | 2008-05-02 | 2008-05-02 | |
| US12/180,994 US7652004B2 (en) | 2007-08-09 | 2008-07-28 | Compounds for the treatment of hepatitis C |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067897A1 true AR067897A1 (es) | 2009-10-28 |
Family
ID=40261456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103488A AR067897A1 (es) | 2007-08-09 | 2008-08-08 | Compuestos para el tratamiento de hepatitis c |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7652004B2 (es) |
| EP (1) | EP2183252B1 (es) |
| JP (1) | JP5465670B2 (es) |
| KR (1) | KR20100066492A (es) |
| CN (1) | CN101821267B (es) |
| AR (1) | AR067897A1 (es) |
| AU (1) | AU2008293845B2 (es) |
| BR (1) | BRPI0814931A2 (es) |
| CA (1) | CA2695781A1 (es) |
| CL (1) | CL2008002353A1 (es) |
| CO (1) | CO6251359A2 (es) |
| EA (1) | EA015978B1 (es) |
| MX (1) | MX2010001416A (es) |
| NZ (1) | NZ583149A (es) |
| PE (1) | PE20090618A1 (es) |
| TW (1) | TW200906418A (es) |
| WO (1) | WO2009029384A2 (es) |
| ZA (1) | ZA201000923B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049622A1 (ja) * | 2003-11-19 | 2005-06-02 | Japan Tobacco Inc. | ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途 |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| DK2209789T3 (da) * | 2007-11-20 | 2012-03-05 | Bristol Myers Squibb Co | Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| MX2010010060A (es) | 2008-03-27 | 2010-09-30 | Bristol Myers Squibb Co | Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados, heterociclicos y aromaticos. |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| WO2010093359A1 (en) * | 2009-02-11 | 2010-08-19 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| CN106986862A (zh) | 2010-12-22 | 2017-07-28 | Abbvie 公司 | 丙型肝炎抑制剂及其用途 |
| JP5915004B2 (ja) * | 2011-06-22 | 2016-05-11 | セントラル硝子株式会社 | ピラゾール化合物の製造方法 |
| US9012657B2 (en) | 2011-06-22 | 2015-04-21 | Central Glass Company, Limited | Method for producing pyrazole compound |
| AU2013290402A1 (en) * | 2012-07-18 | 2015-03-05 | Bristol-Myers Squibb Holdings Ireland | Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2322602T3 (es) | 2004-02-24 | 2009-06-23 | Japan Tobacco, Inc. | Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc. |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| WO2006046030A2 (en) | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7456167B2 (en) | 2006-05-25 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7541351B2 (en) | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7541353B2 (en) | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7521444B2 (en) | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538102B2 (en) | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538103B2 (en) | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2008
- 2008-07-28 US US12/180,994 patent/US7652004B2/en active Active
- 2008-08-01 CN CN2008801108622A patent/CN101821267B/zh not_active Expired - Fee Related
- 2008-08-01 MX MX2010001416A patent/MX2010001416A/es active IP Right Grant
- 2008-08-01 AU AU2008293845A patent/AU2008293845B2/en not_active Ceased
- 2008-08-01 JP JP2010520215A patent/JP5465670B2/ja not_active Expired - Fee Related
- 2008-08-01 WO PCT/US2008/071881 patent/WO2009029384A2/en active Application Filing
- 2008-08-01 BR BRPI0814931-3A2A patent/BRPI0814931A2/pt not_active IP Right Cessation
- 2008-08-01 EA EA201000277A patent/EA015978B1/ru not_active IP Right Cessation
- 2008-08-01 CA CA2695781A patent/CA2695781A1/en not_active Abandoned
- 2008-08-01 NZ NZ583149A patent/NZ583149A/en not_active IP Right Cessation
- 2008-08-01 EP EP08828571.3A patent/EP2183252B1/en not_active Not-in-force
- 2008-08-01 KR KR1020107005086A patent/KR20100066492A/ko not_active Application Discontinuation
- 2008-08-08 PE PE2008001327A patent/PE20090618A1/es not_active Application Discontinuation
- 2008-08-08 CL CL200802353A patent/CL2008002353A1/es unknown
- 2008-08-08 AR ARP080103488A patent/AR067897A1/es unknown
- 2008-08-08 TW TW097130410A patent/TW200906418A/zh unknown
-
2010
- 2010-02-03 CO CO10011252A patent/CO6251359A2/es not_active Application Discontinuation
- 2010-02-08 ZA ZA2010/00923A patent/ZA201000923B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0814931A2 (pt) | 2015-02-03 |
| EA201000277A1 (ru) | 2010-06-30 |
| EP2183252A2 (en) | 2010-05-12 |
| KR20100066492A (ko) | 2010-06-17 |
| US20090074715A1 (en) | 2009-03-19 |
| CL2008002353A1 (es) | 2008-10-24 |
| AU2008293845A1 (en) | 2009-03-05 |
| US7652004B2 (en) | 2010-01-26 |
| WO2009029384A2 (en) | 2009-03-05 |
| MX2010001416A (es) | 2010-03-01 |
| ZA201000923B (en) | 2011-04-28 |
| EP2183252B1 (en) | 2015-01-14 |
| CN101821267A (zh) | 2010-09-01 |
| TW200906418A (en) | 2009-02-16 |
| AU2008293845B2 (en) | 2013-02-14 |
| EA015978B1 (ru) | 2012-01-30 |
| JP5465670B2 (ja) | 2014-04-09 |
| WO2009029384A3 (en) | 2009-05-28 |
| JP2010535787A (ja) | 2010-11-25 |
| CO6251359A2 (es) | 2011-02-21 |
| NZ583149A (en) | 2011-07-29 |
| CN101821267B (zh) | 2013-07-10 |
| PE20090618A1 (es) | 2009-05-16 |
| CA2695781A1 (en) | 2009-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067897A1 (es) | Compuestos para el tratamiento de hepatitis c | |
| CO6180426A2 (es) | Compuesto para el tratamiento de la hepatitis b | |
| AR055165A1 (es) | Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c. | |
| AR061008A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
| AR071684A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| AR073740A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
| AR061053A1 (es) | Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
| NZ515664A (en) | Benzimidazole derivatives useful as respiratory syncytial virus replication inhibitors | |
| MX2009003157A (es) | Pirazoliltienopiridinas terapeuticas. | |
| TW200510431A (en) | Quinazoline derivatives | |
| GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| RS20090249A (en) | Spiroketone acetyl-coa carboxylase inhibotors | |
| AR056319A1 (es) | Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios | |
| AR067542A1 (es) | Compuestos macrociclicos de indol utiles para el tratamiento de hepatitis c | |
| AR057810A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica | |
| ECSP045317A (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| PE20090151A1 (es) | Derivados de pirimidinona y metodos para su uso | |
| UA100003C2 (ru) | Соединения 1,2,4,5-тетрагидро-3н-бензазепина, способ их получения и фармацевтическая композиция, которая их содержит | |
| AR067528A1 (es) | Eteres heterociclicos sustituidos y su uso en trastornos del snc | |
| ECSP066947A (es) | Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |